Longeveron (LGVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Boobalan Pachaiyappan from H.C. Wainwright remains neutral on the stock and has a $6.00 price target.
Boobalan Pachaiyappan has given his Buy rating due to a combination of factors, including recent advancements in Longeveron’s intellectual property portfolio and strong progress in their pipeline programs. The Notice of Allowance for a patent application related to Lomecel-B’s use in aging-related frailty, particularly for vaccine responsiveness, strengthens Longeveron’s market exclusivity and paves the way for significant market opportunities extending to at least 2037. This development enhances the company’s intellectual property estate, potentially serving as a tool for life cycle management and offering unaccounted upside to current forecasts.
Additionally, the company’s steadfast commitment to progressing its registration-enabling Phase 2 study for hypoplastic left heart syndrome (HLHS) by 2024, with expected data release in the second half of 2025, further bolsters confidence. Positive outcomes from this study may lead to a Biologics Licensing Application by mid-2026. Pachaiyappan also notes the promise shown by Lomecel-B in Alzheimer’s disease following favorable Phase 2a data, with regulatory discussions anticipated in the near term. Despite a limited cash runway, the strategic focus on pipeline execution and the potential for future approvals contribute to the analyst’s optimistic outlook, supporting the Buy recommendation and the 12-month target price of $6 per share.
See the top stocks recommended by analysts >>
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LGVN in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Longeveron (LGVN) Company Description:
Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Read More on LGVN:
- Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- UPDATE — Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Longeveron prices $2.36M registered direct offering priced at $1.62 per share
- Longeveron announces new clinical, biomarker results from Phase 2a CLEAR MIND
- Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
